Medidata Solutions (MDSO) Updates FY 2018 Earnings Guidance

Medidata Solutions (NASDAQ:MDSO) issued an update on its FY 2018 earnings guidance on Thursday morning. The company provided earnings per share guidance of $1.48-1.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.57. The company issued revenue guidance of $624-648 million, compared to the consensus revenue estimate of $636.64 million.

NASDAQ:MDSO traded up $2.59 during trading hours on Thursday, reaching $71.86. The stock had a trading volume of 21,455 shares, compared to its average volume of 635,084. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.41 and a quick ratio of 1.41. Medidata Solutions has a 12-month low of $59.60 and a 12-month high of $88.87. The company has a market capitalization of $4.37 billion, a P/E ratio of 87.47, a P/E/G ratio of 4.59 and a beta of 1.44.

Medidata Solutions (NASDAQ:MDSO) last released its earnings results on Thursday, October 18th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.36 by $0.06. The business had revenue of $163.41 million during the quarter, compared to the consensus estimate of $162.09 million. Medidata Solutions had a return on equity of 11.37% and a net margin of 9.13%. The business’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same period last year, the business posted $0.33 earnings per share. As a group, analysts anticipate that Medidata Solutions will post 0.79 earnings per share for the current year.

Several equities analysts have recently weighed in on the company. BidaskClub cut Medidata Solutions from a strong-buy rating to a buy rating in a research report on Tuesday, June 26th. Zacks Investment Research cut Medidata Solutions from a hold rating to a sell rating in a research report on Thursday, June 21st. ValuEngine upgraded Medidata Solutions from a hold rating to a buy rating in a research report on Monday, July 2nd. Royal Bank of Canada set a $98.00 price target on Medidata Solutions and gave the company a buy rating in a research report on Tuesday, July 24th. Finally, Needham & Company LLC cut Medidata Solutions from a buy rating to a hold rating in a research report on Wednesday, July 25th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $87.17.

In related news, Director Robert Taylor sold 5,000 shares of the business’s stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of $73.05, for a total transaction of $365,250.00. Following the completion of the transaction, the director now directly owns 44,036 shares in the company, valued at $3,216,829.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Michael I. Otner sold 9,288 shares of the business’s stock in a transaction dated Tuesday, July 24th. The stock was sold at an average price of $81.03, for a total value of $752,606.64. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,788 shares of company stock valued at $2,069,857. 4.70% of the stock is owned by company insiders.

Medidata Solutions Company Profile

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Read More: Why is the ex-dividend date different from the record date?

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply